

เอกสารอ้างอิง

- [1] Katzung BG., “ *Basic and Clinical Pharmacology,*” 10rd ed, The McGrawHill companies Inc, 2007, pp. 190-194.(ISBN: 978-007-110441-8)
- [2] Golan DE., “*Principle of Pharmacology,*” 2nd ed, Lippincott Williams & Wilkin,2008, pp. 368-370, 377-379.(ISBN: 978-078-178355-2)
- [3] Health Product Vigilance Center, “ *Spontaneous Report of Adverse Drug Reaction 2008,*” Food and Drug Administration, Ministry of Public Health, 2008, pp. 51-54.
- [4] Health Product Vigilance Center, “ *Spontaneous Report of Adverse Drug Reaction 2010,*”Food and Drug Administration, Ministry of Public Health, 2010, pp. 98-107.
- [5] Jorgensen MG., “ Prevalence of amlodipine-related gingival hyperplasia,” *Journal of Clinical Periodontology*, 68, 1997, pp. 676.
- [6] Ellis JS.,“Prevalence of Gingival Overgrowth Induced by Calcium Channel Blockers: A Community-Based Study,” *Journal of Clinical Periodontology*, 70, 1999, pp. 63-67.
- [7] Ono M., “Prevalence of Amlodipine-induced Gingival Overgrowth,” *Journal of Oral-Medicine Sciences*, 9(2), 2010, pp. 96-100.
- [8] Karnik R., “ Prevalence of gingival overgrowth among elderly patients under amlodipine therapy at a large Indian teaching hospital,” *Journal of Gerodontology*, 29(3), 2012, pp. 209-213.
- [9] Carranza FA., “ *Carranza's Clinical Periodontology,*” 10thed, W.B. Saunders Co., 2006, pp. 285-287, 373-390, 918-925.(ISBN: 978-141-602-400-2)
- [10] Lindhe J., “ *Clinical Periodontology and Implant Dentistry,*” 5thed, Blackwell Publishing Co., 2008, pp. 410-413.(ISBN: 978-140-516-099-5)
- [11] Hallmon WM., “ The role of drugs in the pathogenesis of gingival overgrowth,” *Journal of Clinical Periodontology*, 21, 2000, pp. 176-196.
- [12] Lacy CF., Armstrong LL., Goldman MP. and Lance LL.,“*Drug Information Handbook 2010-2011,*” 19thed, Lexi-Comp Inc, 2010, pp. 94-96.(ISBN: 978-159-195279-4)
- [13] องค์การเภสัชกรรม, “S-Amlodipine versus Amlodipine,” R&D Newsletter, ฉบับที่ 2, เมษายน-มิถุนายน 2552, หน้า 4.

- [14] Suwannarong W., “ Drug-Induced Gingival Overgrowth,” *Journal of Khon Kaen Dentistry*, 7(2), 2004, pp. 129-142.
- [15] Meraw SJ., “Medically induced gingival hyperplasia,” *Mayo Clinic Proceedings*, 73, 1998, pp. 1196-1199.
- [16] Srivastava AK., “Management of amlodipine-induced gingival enlargement: Series of three cases” *Journal of Indian Society of Periodontology*, 14, 2009, pp. 279-281.
- [17] Marshall RI., “Medication induced gingival overgrowth,” *Oral Disease*, 4, 1998, pp. 130-151.
- [18] Bagtzoglou AD., “ Drug-Associated Gingival Enlargement,” *Journal of Clinical Periodontology*, 75, 2004, pp. 1424-1431.
- [19] Ishida H., “Factor influencing nifedipine-induced gingival overgrowth in rats,” *Journal of Clinical Periodontology*, 66(5), 1995, pp. 345-350.
- [20] Thomason JM., “ Determinants of gingival overgrowth severity in organ transplant patients. An examination of the role of HLA phenotype.” *Journal of Clinical Periodontology*, 23, 1996, pp. 628-634.
- [21] Cebeci I., “Evaluation of the frequency of HLA determinants in patients with gingival overgrowth induced by cyclosporine-A,” *Journal of Clinical Periodontology*, 23, 1996, pp. 737-742.
- [22] Seymour RA., “ Risk factors for drug-induced gingival overgrowth,” *Journal of Clinical Periodontology*, 27, 2000, pp. 217-223.
- [23] Barak S., “ Gingival hyperplasia caused by nifedipine histopathologic findings,” *Journal of Clinical Periodontology*, 58, 1987, pp. 639.
- [24] Kaur G., “ Association between calcium channel blockers and gingival hyperplasia,” *Journal of Clinical Periodontology*, 37, 2010, pp. 625-630.
- [25] James JA., “ The calcium channel blocker used with cyclosporin has an effect on gingival overgrowth,” *Journal of Clinical Periodontology*, 27, 2000, pp. 109-115.
- [26] Harris TH., “ Complications following the use of sodium diphenylhydantoinate(Dilantin) therapy,” *Journal of Oklahoma State Medicine Association*, 35, 1942, pp. 365.
- [27] Bokenkamp A., “Nifedipine aggravates cyclosporine A-induced hyperplasia,” *Journal of Pediatric Nephrology*, 8, 1994, pp. 181.

- [28] ชัยนัฏธร ปทุมานนท์, “ระบาดวิทยาทางการแพทย์,” โรงพิมพ์สุขโสภา, พ.ศ.2541, หน้า 158-169.
- [29] Greene JC., “The simplified oral hygiene index,” Journal of the American Dental Association, 68, 1964, pp. 7-13.
- [30] ชรินทร์ เหล่ากุลติลล, “ความวิตกกังวลต่อการรับบริการทางทันตกรรมกับสภาวะทันตสุขภาพและปัจจัยที่เกี่ยวข้องของเด็กนักเรียนชั้นมัธยมศึกษาตอนต้น โรงเรียนบ้านกาดวิทยาคม อำเภอแม่วาง จังหวัดเชียงใหม่,” วิทยานิพนธ์สาธารณสุขศาสตรมหาบัณฑิต มหาวิทยาลัยเชียงใหม่, พ.ศ.2552, หน้า 16-19.
- [31] Loe H., “Periodontal disease in pregnancy:Prevalence and severity,” Acta Odontol Scand, 21, 1963, pp. 532-551.
- [32] Viera AJ., “Understanding Inter-observerAgreement:The Kappa Statistic,” Family Medicine, 37, 2005, pp. 360-363.
- [33] Naranjo CA., “Advances in the diagnosis of adverse drug reactions,” Journal of Clinical Pharmacology, 32, 1992, pp. 897-904.
- [34] Livada R., “Calcium channel blocker-induced gingival enlargement,” Journal of Human Hypertension, 28, 2014, pp. 10-14.
- [35] Mejia LM., “Drug-Induced Gingival Hyperplasia Follow-up,” 2012. [ระบบออนไลน์]. แหล่งที่มา <http://emedicine.medscape.com> (22 มกราคม 2555).

ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright © by Chiang Mai University
All rights reserved